Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2020

View Archived Issues

Bromodomain 2-selective BET inhibitors show antitumor effect in pediatric cancer models

Medicenna outlines phase III plans for MDNA-55 in recurrent glioblastoma

NIAID initiates phase I study of SAR-440894

Avalyn advances phase I/II study of AP-101 in IPF

Recce receives ethics approval to initiate phase I/II burn wound study of RECCE-327

CKD-508, second-generation CETP inhibitor with improved safety and efficacy

Medshine Discovery patents Ret inhibitors

Neutrophils are literal obstacle to stroke recovery

Albumin transports proteins across mucosa, into lymph nodes

Insilico Medicine discloses JAK inhibitors

Epizyme presents CREBBP and KAT3B inhibitors

FZD6 as novel biomarker of depression

Ventyx Biosciences discloses TYK2 ligands

WHO Solidarity interim results show repurposed antivirals for COVID-19 have little or no effect

Baylor College of Medicine identifies new antiviral compounds

TRPA1 channel as a new therapeutic target for chronic post-thoracotomy pain

New model created for CFTR gene nonsense mutation W1282X cystic fibrosis

Cellular "pantry" of sorts, lipid droplets double as home security system

Snai1 inhibition may ameliorate right ventricular failure due to pulmonary hypertension

Furin inhibitor BOS-318 seems effective for treating cystic fibrosis

PharmaMar reports data from APLICOV-PC trial with Aplidin in COVID-19

Agios withdraws MAA for Tibsovo for relapsed or refractory AML with IDH1 mutation

Orion's OB-002H for prevention of HIV completes first-in-human study

Aptose begins phase Ia/b study of CG-806 in AML

FDA clears Mereo to begin phase Ib/II basket study of etigilimab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...